Abstract
Dengue virus (DENV), a member of the family Flaviviridae, presents a tremendous threat to global health since an estimated 2.5 billion people worldwide are at risk for epidemic transmission. DENV infections are primarily restricted to sub-tropical and tropical regions; however, there is concern that the virus will spread into new regions including the United States [1]. There are no approved antiviral drugs or vaccines to combat dengue infection, although DENV vaccines have entered Phase 3 clinical trials. Drug discovery and development efforts against DENV and other viral pathogens must overcome specificity, efficacy, safety, and resistance challenges before the shortage of licensed drugs to treat viral infections can be relieved. Current drug discovery methods are largely inefficient and thus relatively ineffective at tackling the growing threat to public health presented by emerging and remerging viral pathogens. This review discusses current and newly implemented structure-based computational efforts to discover antivirals that target the DENV NS3 protease, although it is clear that these computational tools can be applied to most disease targets.
Keywords: Dengue virus (DENV), family Flaviviridae, Dengue Protease Inhibitors, DENV vaccines, malaria, Mosquitoes
Infectious Disorders - Drug Targets
Title: New Approaches to Structure-Based Discovery of Dengue Protease Inhibitors
Volume: 9 Issue: 3
Author(s): S. M. Tomlinson, R. D. Malmstrom and S. J. Watowich
Affiliation:
Keywords: Dengue virus (DENV), family Flaviviridae, Dengue Protease Inhibitors, DENV vaccines, malaria, Mosquitoes
Abstract: Dengue virus (DENV), a member of the family Flaviviridae, presents a tremendous threat to global health since an estimated 2.5 billion people worldwide are at risk for epidemic transmission. DENV infections are primarily restricted to sub-tropical and tropical regions; however, there is concern that the virus will spread into new regions including the United States [1]. There are no approved antiviral drugs or vaccines to combat dengue infection, although DENV vaccines have entered Phase 3 clinical trials. Drug discovery and development efforts against DENV and other viral pathogens must overcome specificity, efficacy, safety, and resistance challenges before the shortage of licensed drugs to treat viral infections can be relieved. Current drug discovery methods are largely inefficient and thus relatively ineffective at tackling the growing threat to public health presented by emerging and remerging viral pathogens. This review discusses current and newly implemented structure-based computational efforts to discover antivirals that target the DENV NS3 protease, although it is clear that these computational tools can be applied to most disease targets.
Export Options
About this article
Cite this article as:
Tomlinson M. S., Malmstrom D. R. and Watowich J. S., New Approaches to Structure-Based Discovery of Dengue Protease Inhibitors, Infectious Disorders - Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/1871526510909030327
DOI https://dx.doi.org/10.2174/1871526510909030327 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipoxin and Synthetic Lipoxin Analogs: An Overview of Anti- Inflammatory Functions and New Concepts in Immunomodulation
Inflammation & Allergy - Drug Targets (Discontinued) Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Host Immune Responses to Aeromonas Virulence Factors
Current Immunology Reviews (Discontinued) PI3K-Akt Signaling and Viral Infection
Recent Patents on Biotechnology Regulatory T Cells and Tolerogenic Dendritic Cells as Critical Immune Modulators in Atherogenesis
Current Pharmaceutical Design Astrocyte Infection by HIV-1: Mechanisms of Restricted Virus Replication, and Role in the Pathogenesis of HIV-1-Associated Dementia
Current HIV Research Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Progressive Supranuclear Palsy: What Do We Know About it?
Current Medicinal Chemistry Nanomedicine in Therapeutic Intervention of Tuberculosis Meningitis
Current Nanoscience Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Transgenic Mice as a Model for Alzheimers Disease
Current Alzheimer Research The Genetic Basis of Human Cytomegalovirus Resistance and Current Trends in Antiviral Resistance Analysis
Infectious Disorders - Drug Targets Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Aryl- and Heteroaryl-Thiosemicarbazone Derivatives and Their Metal Complexes: A Pharmacological Template
Recent Patents on Anti-Cancer Drug Discovery The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design PTD/CPP Peptide-Mediated Delivery of siRNAs
Current Pharmaceutical Design Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Bioinformatic Analysis of HIV-1 Entry and Pathogenesis
Current HIV Research